Using the ProteOn™ XPR36 to Characterize Human-Derived Monoclonal Antibodies Against Influenza Virus





The interactive transcript could not be loaded.


Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 14, 2012

For more information, visit http://www.bio-rad.com/yt/8/proteonxpr36.
Different strains of Influenza virus include a great diversity of antigenic proteins, often requiring annual vaccination for strain-specific protection. This webinar focuses on the use of the ProteOn XPR36 system to determine the cross-reactivity and binding kinetics of a panel of human-derived monoclonal antibodies against the H3 hemagglutinin protein in multiple Influenza strains. The ability to robustly measure the binding affinities of a panel of antibodies with numerous antigens using the ProteOn system is a powerful platform that is applicable to many experimental systems. It allows real-time comparison of multiple interactions on a single chip, and provides high throughput in obtaining the screening result.

Dr Lisa Scalfone, Postdoctoral Fellow
Stanford University School of Medicine


We Are Bio-Rad.

Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.

Connect with Bio-Rad Online:
Website: http://www.bio-rad.com/
LinkedIn: https://www.linkedin.com/company/1613...
Facebook: https://www.facebook.com/biorad/
Twitter: https://twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs


When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...